Interactions between Bupropion and 3,4-Methylenedioxymethamphetamine in Healthy Subjects

@article{Schmid2015InteractionsBB,
  title={Interactions between Bupropion and 3,4-Methylenedioxymethamphetamine in Healthy Subjects},
  author={Yasmin Schmid and Anna Rickli and Antonia Schaffner and Urs Duthaler and Eric Grouzmann and C{\'e}dric M. Hysek and Matthias E. Liechti},
  journal={The Journal of Pharmacology and Experimental Therapeutics},
  year={2015},
  volume={353},
  pages={102 - 111}
}
  • Y. Schmid, A. Rickli, M. Liechti
  • Published 1 April 2015
  • Biology, Psychology
  • The Journal of Pharmacology and Experimental Therapeutics
3,4-Methylenedioxymethamphetamine (MDMA; “ecstasy”) is a popular recreational drug. The aim of the present study was to explore the role of dopamine in the psychotropic effects of MDMA using bupropion to inhibit the dopamine and norepinephrine transporters through which MDMA releases dopamine and norepinephrine. The pharmacodynamic and pharmacokinetic interactions between bupropion and MDMA in 16 healthy subjects were investigated using a double-blind, placebo-controlled, crossover design… 

Figures and Tables from this paper

Safety pharmacology of acute MDMA administration in healthy subjects
TLDR
MDMA administration was overall safe in physically and psychiatrically healthy subjects and in a medical setting, however, the risks of MDMA are likely higher in patients with cardiovascular disease and remain to be investigated in Patients with psychiatric disorders.
Key interindividual determinants in MDMA pharmacodynamics
TLDR
The aim of this review is to present the main interindividual determinants in MDMA pharmacodynamics, with special emphasis on sex-gender, race-ethnicity, genetic differences, interactions, and MDMA acute toxicity, as well as possible therapeutic use.
Prediction of MDMA response in healthy humans: a pooled analysis of placebo-controlled studies
TLDR
Although MDMA plasma concentration was the strongest predictor, several personality traits and mood state variables additionally explained variance in the response to MDMA, confirming that both pharmacological and non-pharmacological variables influence the response of MDMA.
MDMA interactions with pharmaceuticals and drugs of abuse
TLDR
This article provides an overview of the MDMA-DIs with pharmaceuticals and drugs of abuse and points out the relevance of MDMA-DI’s when MDMA is co-administered with Pharmaceuticals that are metabolized by the CYP2D6 due to MDMA inhibitory action.
No major role of norepinephrine transporter gene variations in the cardiostimulant effects of MDMA
TLDR
Genetic polymorphisms of the SLC6A2 gene weakly moderated the acute cardiovascular response to MDMA in controlled studies and may play a minor role in adverse cardiovascular events when MDMA is used recreationally.
No Influence of Dopamine System Gene Variations on Acute Effects of MDMA
TLDR
None of the tested genetic polymorphisms within the DA system altered effects of MDMA when adjusting for multiple comparisons, indicating that genetic variations in genes coding for players of theDA system are unlikely to explain interindividual variations in the acute effects of ecstasy in humans.
Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine.
TLDR
The synthesis of MDMA is detailed as well as its pharmacology, metabolism, adverse effects, and potential use in medicine, which discusses its history and why it is perhaps the most important compound for the future of psychedelic science.
Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database
TLDR
Several drug classes (MDMA metabolites or analogs, anesthetics, muscle relaxants, amphetamines and stimulants, benzodiazepines, ethanol, opioids), four antidepressants and olanzapine demonstrated increased odds ratios for the reported risk of death among MDMA users.
...
1
2
3
4
...

References

SHOWING 1-10 OF 77 REFERENCES
Pharmacological Interaction between 3,4-Methylenedioxymethamphetamine (Ecstasy) and Paroxetine: Pharmacological Effects and Pharmacokinetics
TLDR
It seems that paroxetine could interact with MDMA at pharmacodynamic (serotonin transporter) and pharmacokinetic (CYP2D6 metabolism) levels, whereas MDMA alone produced the prototypical effects of the drug.
The Norepinephrine Transporter Inhibitor Reboxetine Reduces Stimulant Effects of MDMA (“Ecstasy”) in Humans
TLDR
Reboxetine reduced the effects of MDMA including elevations in plasma levels of NE, increases in blood pressure and heart rate, subjective drug high, stimulation, and emotional excitation.
Effects of the α2-Adrenergic Agonist Clonidine on the Pharmacodynamics and Pharmacokinetics of 3,4-Methylenedioxymethamphetamine in Healthy Volunteers
TLDR
The present findings do not support a role for α2-adrenergic receptor agonists in the prevention of psychostimulant dependence and indicate that vesicular release of norepinephrine, which is inhibited by clonidine, does not critically contribute to the effects of MDMA in humans.
Duloxetine Inhibits Effects of MDMA (“Ecstasy") In Vitro and in Humans in a Randomized Placebo-Controlled Laboratory Study
TLDR
The findings confirm the important role of MDMA-induced 5-HT and NE release in the psychotropic effects of MDMA and suggest duloxetine may be useful in the treatment of psychostimulant dependence.
Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone or in combination.
TLDR
The combined use of methylphenidate and MDMA does not produce more psychoactive effects compared with either drug alone, but potentially enhances cardiovascular and adverse effects.
The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans
TLDR
These results suggest that blockade of 5-HT reuptake by fluoxetine can dampen the effects of MDMA and further supports the role of5-HT in its behavioral effects in humans.
The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3, 4-methylenedioxymethamphetamine (‘Ecstasy’) in healthy volunteers
TLDR
It is suggested that physiological effects of MDMA in humans are partially due to an interaction of MDMA with the serotonin carrier and a subsequent release of serotonin.
MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment
TLDR
The affinity of ecstasy for the human SERT in transfected cells does not clarify the apparent selective toxicity of MDMA for serotonin neurons, although conceivably, its higher efficacy for stimulating 5-HT release may be a distinguishing factor.
Contribution of Cytochrome P450 2D6 to 3,4-Methylenedioxymethamphetamine Disposition in Humans
TLDR
The contribution of CYP2D6 to MDMA metabolism in humans is not >30%, therefore other CYP isoenzymes may contribute to O-demethylenation of MDMA, once the enzyme is inhibited.
...
1
2
3
4
5
...